Richard E Pratley1. 1. Department of Medicine, Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology, Diabetes and Metabolism, University of Vermont College of Medicine, Burlington, USA. richard.pratley@uvm.edu
Abstract
CONTEXT: Impairment of incretin activity is now recognized as integral to the metabolic derangement underlying type 2 diabetes. Glucoregulatory agents that target the incretin system have recently been developed, and the place of these drugs in the treatment of type 2 diabetes can be assessed based on a growing body of clinical data. EVIDENCE ACQUISITION: A PubMed search was conducted to identify clinical studies of incretin therapies in type 2 diabetes. Article reference lists were also searched for relevant information, and supplemental material such as conference abstracts, drug prescribing information, and treatment guidelines were included as appropriate. EVIDENCE SYNTHESIS: Two classes of therapies target the incretin system. The first, glucagon-like peptide-1 (GLP-1) agonists (exemplified by exenatide and liraglutide), have demonstrated considerable efficacy in clinical trials, reducing hemoglobin A1c (HbA1c) by up to 1.3%, decreasing fasting and postprandial glucose concentrations, reducing weight by approximately 3.0 kg, and improving cardiovascular risk factors. The second class, the dipeptidyl peptidase-4 inhibitors (such as sitagliptin and vildagliptin) rely on production of endogenous GLP-1 and act by reducing its turnover. The dipeptidyl peptidase-4 (DPP-4) inhibitors produce modest reductions in HbA1c (< 1%) compared with GLP-1 agonists and are generally weight-neutral. Neither GLP-1 agonists nor DPP-4 inhibitors cause hypoglycemia unless used with other agents known to increase risk. CONCLUSIONS: GLP-1 agonists and DPP-4 inhibitors provide a valuable new treatment option for patients with type 2 diabetes and may be associated with a wider range of therapeutic benefits than older drugs.
CONTEXT: Impairment of incretin activity is now recognized as integral to the metabolic derangement underlying type 2 diabetes. Glucoregulatory agents that target the incretin system have recently been developed, and the place of these drugs in the treatment of type 2 diabetes can be assessed based on a growing body of clinical data. EVIDENCE ACQUISITION: A PubMed search was conducted to identify clinical studies of incretin therapies in type 2 diabetes. Article reference lists were also searched for relevant information, and supplemental material such as conference abstracts, drug prescribing information, and treatment guidelines were included as appropriate. EVIDENCE SYNTHESIS: Two classes of therapies target the incretin system. The first, glucagon-like peptide-1 (GLP-1) agonists (exemplified by exenatide and liraglutide), have demonstrated considerable efficacy in clinical trials, reducing hemoglobin A1c (HbA1c) by up to 1.3%, decreasing fasting and postprandial glucose concentrations, reducing weight by approximately 3.0 kg, and improving cardiovascular risk factors. The second class, the dipeptidyl peptidase-4 inhibitors (such as sitagliptin and vildagliptin) rely on production of endogenous GLP-1 and act by reducing its turnover. The dipeptidyl peptidase-4 (DPP-4) inhibitors produce modest reductions in HbA1c (< 1%) compared with GLP-1 agonists and are generally weight-neutral. Neither GLP-1 agonists nor DPP-4 inhibitors cause hypoglycemia unless used with other agents known to increase risk. CONCLUSIONS:GLP-1 agonists and DPP-4 inhibitors provide a valuable new treatment option for patients with type 2 diabetes and may be associated with a wider range of therapeutic benefits than older drugs.
Authors: L Blonde; E J Klein; J Han; B Zhang; S M Mac; T H Poon; K L Taylor; M E Trautmann; D D Kim; D M Kendall Journal: Diabetes Obes Metab Date: 2006-07 Impact factor: 6.577
Authors: M A Nauck; M Hompesch; R Filipczak; T D T Le; M Zdravkovic; J Gumprecht Journal: Exp Clin Endocrinol Diabetes Date: 2006-09 Impact factor: 2.949
Authors: M B Toft-Nielsen; M B Damholt; S Madsbad; L M Hilsted; T E Hughes; B K Michelsen; J J Holst Journal: J Clin Endocrinol Metab Date: 2001-08 Impact factor: 5.958
Authors: Pablo Aschner; Mark S Kipnes; Jared K Lunceford; Matilde Sanchez; Carolyn Mickel; Debora E Williams-Herman Journal: Diabetes Care Date: 2006-12 Impact factor: 19.112
Authors: A J Garber; J E Foley; M A Banerji; P Ebeling; S Gudbjörnsdottir; R-P Camisasca; A Couturier; M A Baron Journal: Diabetes Obes Metab Date: 2008-02-18 Impact factor: 6.577